Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality, day 30 73% Improvement Relative Risk Mortality, day 15 75% Hospitalization, day 30 84% Hospitalization, day 15 89% c19early.com/pl Zhou et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
Zhou, 13,657 patient paxlovid early treatment PSM study: 73% lower mortality [p<0.0001] and 84% lower hospitalization [p<0.0001] https://c19p.org/zhou8
copied to clipboard
Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study
Zhou et al., medRxiv, doi:10.1101/2022.09.13.22279908 (Preprint)
14 Sep 2022    Source   PDF   Share   Tweet
Pfizer retrospective 2,811 high risk COVID-19 patients treated with paxlovid in the US, and 10,849 matched controls, showing lower risk of mortality and hospitalization with treatment.
risk of death, 73.0% lower, RR 0.27, p < 0.001, treatment 7 of 2,808 (0.2%), control 100 of 10,849 (0.9%), NNT 149, propensity score matching, day 30.
risk of death, 75.2% lower, RR 0.25, p < 0.001, treatment 5 of 2,808 (0.2%), control 78 of 10,849 (0.7%), NNT 185, propensity score matching, day 15.
risk of hospitalization, 84.0% lower, HR 0.16, p < 0.001, treatment 34 of 2,808 (1.2%), control 752 of 10,849 (6.9%), NNT 17, propensity score matching, Cox proportional hazards, day 30.
risk of hospitalization, 89.0% lower, HR 0.11, p < 0.001, treatment 22 of 2,808 (0.8%), control 708 of 10,849 (6.5%), NNT 17, propensity score matching, Cox proportional hazards, day 15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhou et al., 14 Sep 2022, retrospective, USA, preprint, median age 62.0, 9 authors, study period 22 December, 2021 - 8 June, 2022.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit